India's Glenmark to start new phase 3 clinical trial of Covid-19 drug combination
Image Credit: shortpedia
Glenmark Pharmaceuticals on Tuesday announced a new randomised, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy. A total of 158 hospitalised patients of moderate Covid-19 infection will be enrolled in the combination study and randomised in two groups. The company will also test Favipiravir for monotherapy option.